XTL Biopharm SP (XTLB) Swings to Q3 Loss
Tweet
Share
E-mailGet Alerts XTLB Hot Sheet
Join SI Premium – FREE
XTL Biopharm SP (Nasdaq: XTLB) reported Q3 EPS of $-0.00, versus $0.00 reported last year. Revenue was $287 thousand, versus $473 thousand posted in Q313.
For earnings history and earnings-related data on XTL Biopharm SP (XTLB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
- Epsilon Energy Ltd. (EPSN) Reports Q2 EPS of $0.23
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
